Haleon to invest $54 mln in US R&D centre to ... invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.

I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered ...

In this article, we are going to take a look at where Haleon plc (NYSE:HLN) stands against other stocks that lead Monday’s charge amid market bloodbath. The stock market kicked off the trading ...

Shares of Haleon PLC HLN advanced 2.52% to £3.94 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.41% to 8,768.01.

Good morning, everyone. Welcome to Haleon's Full Year 2024 Q&A call. I'm Jo Russell, Head of Investor Relations. And I'm joined this morning by Brian McNamara, Chief Executive Officer; and Dawn ...

Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion.

The projected fair value for Haleon is UK£5.19 based on 2 Stage Free Cash Flow to Equity Current share price of UK£3.91 suggests Haleon is potentially 25% undervalued Analyst price target for ...

Haleon reported FY24 revenue of £11.23B ($14.19B), down 0.6%, with 5% organic growth. Adjusted operating profit fell 6.5% to £2.50B. 2025 guidance projects 4-6% organic revenue growth, with ...

Berenberg analyst Bethan Davies raised the firm’s price target on Haleon (HLN) to 457 GBp from 456 GBp and keeps a Buy rating on the shares. See what stocks are receiving Strong Buy ratings from ...

Haleon is one of the largest consumer healthcare companies in the world. Over the last few years, Haleon has achieved a more rationalized operation by divesting multiple non-strategic brands ...